Stock & Company Details
BioAtla Inc $BCAB
Price:
N/A
N/A
N/A
$5.2M
52 Week High:
N/A
10 Day Average Volume:
N/A
-0.04
50 Day Moving Average:
N/A
52 Week Low:
N/A
30 Day Average Volume:
N/A
N/A
N/A
N/A
30 Day Change:
N/A
3 Month Change:
N/A
Health Technology
BCAB technical indicators
Latest BioAtla Inc (BCAB) indicator readings as of 2026-08-28.
BCAB's 14-day RSI is 20.2, in oversold territory. At $1.74 it is trading 21.1% below its 200-day moving average of $2.20, and below its 50-day average of $3.53. Price sits below the lower Bollinger Band ($2.48 to $3.92). ADX reads 16.9, indicating a range-bound market rather than a trend.
Select a strategy to see its performance
Backtested on this stock over recent history.
| Strategy | Trend | Return | Win rate |
|---|---|---|---|
| MACD Momentum Momentum Buy when MACD turns positive (crosses above zero) and RSI confirms momentum above 50; sell when MACD falls back below zero. | – | – | |
| RSI Reversal Mean reversion Buy when RSI falls below 30 (oversold), sell when it climbs above 70 (overbought). | – | – | |
| Volatility Breakout Volatility Buy when price closes above the upper Bollinger Band, sell on reversion to the 20-day average. | – | – | |
| Strong-Trend Pullback Trend + timing In strongly trending stocks (ADX above 25), buy short-term dips (Stochastic below 30) and sell into overbought (above 80). | – | – |
Overview
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of highly specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise Mecbotamab vedotin, Ozuriftabmab vedotin, BA3071, and Bispecific antibody programs.
Finance Bot
Ask your questions
Start by typing a question below.
